Aptevo Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Seattle, WA
APVO chart
What traders are saying about $APVO
Latest postsAptevo Therapeutics Inc. news
- Aptevo Therapeutics (NASDAQ:APVO) Penny Stock Drops 6% Pre-Market Despite Strong Leukemia Data
kalkine.ca ·
- APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate
Yahoo Finance ·
- Aptevo Therapeutics Reveals 10 Newly Diagnosed AML Patients Progress to Stem Cell Transplant After Mipletamig Combo Therapy
Kalkine Media ·
- Form 8K Aptevo Therapeutics Inc For: 26 October By Investing.com
Investing.com India ·
- Aptevo Therapeutics Mipletamig Combination Enabled 21% Of Frontline Aml Patients To Advance To Stem Cell Transplant
TradingView ·
- Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Yahoo Finance ·
- 10 of 47 newly diagnosed blood cancer patients reached a donor stem cell transplant. It may offer a chance of cure.
Stock Titan ·
- Aptevo Therapeutics Inc. Estimates – NASDAQ:APVO
TradingView ·
- Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
TradingView ·
- Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Yahoo Finance ·
- Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Yahoo Finance ·
- Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
investorshub.advfn.com ·
Aptevo Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $3.1M |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M |
| Diluted EPS | $-87.27 | $-31460.23 | $-2316.83 | $1.57 |
| Total assets (year end) | $27.2M | $15.6M | $24.8M | $34.2M |
| Cash and equivalents (year end) | $21.6M | $8.7M | $16.9M | $22.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Aptevo Therapeutics Inc.
- Ticker
- APVO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Seattle, WA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1671584
Frequently asked questions
What exchange is Aptevo Therapeutics Inc. listed on?
Aptevo Therapeutics Inc. trades on the Nasdaq under the ticker symbol APVO.
What industry is Aptevo Therapeutics Inc. in?
Aptevo Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Aptevo Therapeutics Inc. headquartered?
Aptevo Therapeutics Inc.'s business address on file with the SEC is in Seattle, WA.
When does Aptevo Therapeutics Inc.'s fiscal year end?
Aptevo Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Aptevo Therapeutics Inc. report?
Aptevo Therapeutics Inc. reported $3.1M in revenue for calendar year 2022, according to its SEC filings.